JPWO2020123662A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020123662A5
JPWO2020123662A5 JP2021533356A JP2021533356A JPWO2020123662A5 JP WO2020123662 A5 JPWO2020123662 A5 JP WO2020123662A5 JP 2021533356 A JP2021533356 A JP 2021533356A JP 2021533356 A JP2021533356 A JP 2021533356A JP WO2020123662 A5 JPWO2020123662 A5 JP WO2020123662A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
domain
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021533356A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512234A5 (https=
JP2022512234A (ja
JP7444886B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/065741 external-priority patent/WO2020123662A2/en
Publication of JP2022512234A publication Critical patent/JP2022512234A/ja
Publication of JP2022512234A5 publication Critical patent/JP2022512234A5/ja
Publication of JPWO2020123662A5 publication Critical patent/JPWO2020123662A5/ja
Priority to JP2024025175A priority Critical patent/JP7811315B2/ja
Application granted granted Critical
Publication of JP7444886B2 publication Critical patent/JP7444886B2/ja
Priority to JP2025279839A priority patent/JP2026053563A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021533356A 2018-12-11 2019-12-11 補体関連疾患のための融合タンパク質構築物 Active JP7444886B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024025175A JP7811315B2 (ja) 2018-12-11 2024-02-22 補体関連疾患のための融合タンパク質構築物
JP2025279839A JP2026053563A (ja) 2018-12-11 2025-12-24 補体関連疾患のための融合タンパク質構築物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862778014P 2018-12-11 2018-12-11
US62/778,014 2018-12-11
PCT/US2019/065741 WO2020123662A2 (en) 2018-12-11 2019-12-11 Fusion protein constructs for complement associated disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024025175A Division JP7811315B2 (ja) 2018-12-11 2024-02-22 補体関連疾患のための融合タンパク質構築物

Publications (4)

Publication Number Publication Date
JP2022512234A JP2022512234A (ja) 2022-02-02
JP2022512234A5 JP2022512234A5 (https=) 2023-07-31
JPWO2020123662A5 true JPWO2020123662A5 (https=) 2023-07-31
JP7444886B2 JP7444886B2 (ja) 2024-03-06

Family

ID=71076704

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021533356A Active JP7444886B2 (ja) 2018-12-11 2019-12-11 補体関連疾患のための融合タンパク質構築物
JP2024025175A Active JP7811315B2 (ja) 2018-12-11 2024-02-22 補体関連疾患のための融合タンパク質構築物
JP2025279839A Pending JP2026053563A (ja) 2018-12-11 2025-12-24 補体関連疾患のための融合タンパク質構築物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024025175A Active JP7811315B2 (ja) 2018-12-11 2024-02-22 補体関連疾患のための融合タンパク質構築物
JP2025279839A Pending JP2026053563A (ja) 2018-12-11 2025-12-24 補体関連疾患のための融合タンパク質構築物

Country Status (13)

Country Link
US (1) US20240301043A1 (https=)
EP (1) EP3893916A4 (https=)
JP (3) JP7444886B2 (https=)
KR (2) KR102762828B1 (https=)
CN (1) CN113660944A (https=)
AU (2) AU2019398214C1 (https=)
IL (1) IL283841A (https=)
MA (1) MA54468A (https=)
MX (1) MX2021006930A (https=)
MY (1) MY209796A (https=)
PH (1) PH12021551398A1 (https=)
SG (1) SG11202106073QA (https=)
WO (1) WO2020123662A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018075783A2 (en) * 2016-10-20 2018-04-26 President And Fellows Of Harvard College In vitro and cell based assays for measuring the activity of botulinum neurotoxins
CA3141778A1 (en) * 2019-06-12 2020-12-17 CSL Innovation Pty Ltd Soluble complement receptor type 1 variant conjugates and uses thereof
AU2021293174A1 (en) 2020-06-14 2023-01-19 Vertex Pharmaceuticals Incorporated Complement Factor I-related compositions and methods
CN114778418B (zh) * 2022-06-17 2022-09-27 深圳安侣医学科技有限公司 基于显微放大数字图像的血红蛋白分析方法及系统
CN117624347A (zh) * 2022-08-30 2024-03-01 天辰生物医药(苏州)有限公司 抗人补体c5抗体以及其融合蛋白
EP4617287A1 (en) * 2022-11-10 2025-09-17 Longbio Pharma (Suzhou) Co., Ltd. Complement-inhibitory hybrid protein mutant and antibody fusion protein thereof
CN118373913B (zh) * 2024-05-08 2024-11-01 上海百英生物科技股份有限公司 一种抗人Tim-3单克隆抗体及其制备方法
CN118878672A (zh) * 2024-08-01 2024-11-01 河北康立德生物科技有限公司 一种抗曲霉半乳甘露聚糖单克隆抗体、试剂盒及其应用
CN119638823A (zh) * 2024-12-10 2025-03-18 中国医学科学院病原生物学研究所 检测a35r蛋白的单克隆抗体及其应用
CN119431565B (zh) * 2025-01-10 2025-04-08 成都迈科康生物科技有限公司 一种抗hpv16型e6蛋白和e7蛋白的抗体、检测产品及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
EP1284752A4 (en) * 2000-04-26 2004-08-18 Elusys Therapeutics Inc BISPECIFIC MOLECULES AND USES THEREOF
US7708999B2 (en) * 2001-12-28 2010-05-04 Kyowa Hakko Kirin Co., Ltd. Remedies for arthritis
WO2005063815A2 (en) * 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
WO2006042252A2 (en) * 2004-10-08 2006-04-20 Potentia Pharmeceuticals, Inc. Viral complement control proteins for eye disorders
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US9815890B2 (en) * 2010-06-22 2017-11-14 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the C3d fragment of complement component 3
AU2011336702B2 (en) 2010-11-29 2016-10-06 Novelmed Therapeutics, Inc. Neoantibodies for diagnosing tissue injury
AU2013302441B2 (en) * 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
AU2014209350B8 (en) * 2013-01-23 2019-04-18 Department Of Veterans Affairs (Us) Targeting constructs based on natural antibodies and uses thereof
AU2014348683B2 (en) * 2013-11-18 2020-11-05 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
US10035848B2 (en) 2014-01-08 2018-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody targeting cell surface deposited complement protein C3d and use thereof
ES2865825T3 (es) * 2014-04-01 2021-10-18 Rubius Therapeutics Inc Procedimientos y composiciones para inmunomodulación
CN106687123A (zh) * 2014-06-05 2017-05-17 科罗拉多州大学评议会 Map44多肽和基于天然抗体的构建体及其用途
CR20170383A (es) * 2015-01-23 2017-11-22 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123

Similar Documents

Publication Publication Date Title
GB2583560A (en) Fusion protein constructs for complement associated disease
EP3313437A1 (en) A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
JP7444886B2 (ja) 補体関連疾患のための融合タンパク質構築物
CN110538321B (zh) 一种cd47抗体药物组合物及其用途
RU2014106652A (ru) Ингибирующие моноклональные антитела против фактора xii/xiia и их применения
RS62857B1 (sr) Unapređeni varijabilni domeni imunoglobulina koji vezuju serumski albumin
ES2993153T3 (en) Pan elr+ cxc chemokine antibodies
US9932397B2 (en) VEGFA/Ang2 Compounds
JP2024020446A (ja) 抗ｃ５抗体組み合わせ物およびその使用
JPWO2020123662A5 (https=)
CN110732023A (zh) 一种her2抗体药物组合物及其用途
CN103003302A (zh) 人源化和嵌合抗-备解素抗体
AU2015264550B2 (en) Ang2 antibodies
US20250034277A1 (en) Method for preventing and/or treating thromboembolic diseases
WO2018223958A1 (zh) 一种含c-Met抗体药物偶联物的药物组合物及其用途
CN108431039A (zh) 改进的p2x7受体结合剂和包含其的多肽
CA3234626A1 (en) Dosing regimens of factor xi/xia antibodies
AU2023287807A1 (en) Combination therapies with an anti-factor xi/factor xia antibody
RU2021120303A (ru) Конструкции слитого белка для заболевания, связанного с комплементом
EP4729541A1 (en) Anti- igfbp7 antibodies and uses thereof
HK40128682A (zh) 结合c1s的抗体和其用途
TW202535461A (zh) 使用抗ｓｉｒｐａ抗體治療肝臟疾病或病症
JP2023546461A (ja) 網膜の血栓性疾患の処置のための抗セマフォリン３ａ抗体及びその使用
EA051976B1 (ru) Применение антитела против sema3a для лечения окклюзии вен сетчатки
HK1195319B (zh) Il-6结合分子